PE20001226A1 - Formulacion liquida con formoterol, apropiada para almacenar - Google Patents

Formulacion liquida con formoterol, apropiada para almacenar

Info

Publication number
PE20001226A1
PE20001226A1 PE1999001045A PE00104599A PE20001226A1 PE 20001226 A1 PE20001226 A1 PE 20001226A1 PE 1999001045 A PE1999001045 A PE 1999001045A PE 00104599 A PE00104599 A PE 00104599A PE 20001226 A1 PE20001226 A1 PE 20001226A1
Authority
PE
Peru
Prior art keywords
acid
preference
formoterol
storage
concentrate
Prior art date
Application number
PE1999001045A
Other languages
English (en)
Inventor
Hochrainer Dieter
Zierenberg Bernd
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20001226A1 publication Critical patent/PE20001226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN CONCENTRADO DE SUSTANCIA ACTIVA EXENTO DE AGENTE PROPULSOR QUE CONTIENE a)DE 75 mg/ml A 500 mg/ml DE FORMOTEROL EN FORMA DE BASE LIBRE, b)UN DISOLVENTE O SUSPENSION DE PREFERENCIA LIQUIDO POLAR COMO AGUA, UNA SOLUCION ACUOSA DE UNA SAL, DE PREFERENCIA UNA SOLUCION DE CLORURO DE SODIO, ETANOL O UNA MEZCLA; c)UNA SUSTANCIA TENSOACTIVA TAL COMO ESTERES DE SORBITAN, DE PREFERENCIA TRIOLEATO DE SORBITAN, ACIDO OLEICO, LECITINA; d)UN ACIDO TAL COMO ACIDO CLORHIDRICO, ACIDO NITRICO, ACIDO SULFURICO, ENTRE OTROS; e)UN AGENTE CONSERVANTE, e)UN ANTIOXIDANTE, f)UN COMPUESTO FORMADOR DE COMPLEJOS TAL COMO EDTA; g)OTRAS SUSTANCIAS ACTIVAS TAL COMO BETASIMPATICOMIMETICOS, ANTICOLINERGICOS, ANTIALERGICOS, ANTAGONISTAS DE LEUCOTRIENOS, ESTEROIDES; EL pH DEL CONCENTRADO ES DE 2 A 7. EL FORMOTEROL INHIBE LA LIBERACION DE LEUCOTRIENOS, HISTAMINAS, ENTRE OTROS; POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS
PE1999001045A 1998-10-17 1999-10-15 Formulacion liquida con formoterol, apropiada para almacenar PE20001226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19847969A DE19847969A1 (de) 1998-10-17 1998-10-17 Lagerfähig flüssige Formulierung mit Formoterol

Publications (1)

Publication Number Publication Date
PE20001226A1 true PE20001226A1 (es) 2000-11-01

Family

ID=7884831

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001045A PE20001226A1 (es) 1998-10-17 1999-10-15 Formulacion liquida con formoterol, apropiada para almacenar

Country Status (14)

Country Link
US (1) US6150418A (es)
AR (1) AR020830A1 (es)
AT (1) ATE218331T1 (es)
AU (1) AU764126B2 (es)
CO (2) CO5271759A1 (es)
DE (1) DE19847969A1 (es)
EG (1) EG23820A (es)
MY (1) MY124329A (es)
PE (1) PE20001226A1 (es)
RS (1) RS49907B (es)
SA (1) SA99200700B1 (es)
TW (1) TW562676B (es)
UA (1) UA71585C2 (es)
ZA (1) ZA200103056B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
AU2001294808A1 (en) * 2000-09-29 2002-04-08 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
US20020193394A1 (en) * 2001-03-13 2002-12-19 Bernd Disse Compounds for treating inflammatory diseases
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
DK1273292T3 (da) * 2001-07-02 2004-10-04 Chiesi Farma Spa Optimeret tobramycinformulering til aerosoldannelse
MEP30108A (en) * 2002-03-01 2010-06-10 Chiesi Farmaceutici S P Formoterol superfine formulation
AU2003251303A1 (en) * 2002-05-21 2003-12-12 Glaxo Group Limited Pharmaceutical products and methods of manufacture
US20040166065A1 (en) * 2002-08-14 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation comprising an anticholinergic
AU2007231727B2 (en) * 2002-09-03 2010-12-16 Kos Life Sciences, Inc. Water stabilized medicinal aerosol formulation
EP1539284B1 (en) * 2002-09-06 2020-01-29 Philip Morris Products S.a.s. Aerosol generating device and method for generating aerosols
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10345065A1 (de) * 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
UA88894C2 (ru) * 2004-02-27 2009-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением
KR20070000476A (ko) * 2004-02-27 2007-01-02 키에시 파르마슈티시 엣스. 피. 에이. 압축화 계량된 도스흡입용 안정된 약제용액 제제
EP1742625A1 (en) * 2004-04-05 2007-01-17 Sepracor, Inc. (r,r)-formoterol in combination with other pharmacological agents
ITRM20050022A1 (it) 2005-01-19 2006-07-20 Italchimici S P A Formulazione farmaceutica di una soluzione stabile di glicole propilenico contenente formoterolo per via inalatoria e suo procedimento di preparazione.
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
AU2013246692A1 (en) * 2012-04-11 2014-10-02 Cipla Limited Pharmaceutical composition comprising arformoterol and fluticasone furoate
WO2020263994A1 (en) * 2019-06-27 2020-12-30 Cai Gu Huang Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU675633B2 (en) * 1991-12-18 1997-02-13 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
ATE213946T1 (de) * 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
ES2122261T3 (es) * 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations

Also Published As

Publication number Publication date
CO5261514A1 (es) 2003-03-31
SA99200700B1 (ar) 2006-06-10
EG23820A (en) 2007-09-19
RS49907B (sr) 2008-09-29
MY124329A (en) 2006-06-30
AU6201999A (en) 2000-05-08
YU26701A (sh) 2005-07-19
US6150418A (en) 2000-11-21
UA71585C2 (uk) 2004-12-15
TW562676B (en) 2003-11-21
ATE218331T1 (de) 2002-06-15
AU764126B2 (en) 2003-08-14
ZA200103056B (en) 2002-01-23
CO5271759A1 (es) 2003-04-30
AR020830A1 (es) 2002-05-29
DE19847969A1 (de) 2000-04-20

Similar Documents

Publication Publication Date Title
PE20001226A1 (es) Formulacion liquida con formoterol, apropiada para almacenar
FI106842B (fi) Menetelmä tulehduksen hoitoon terapeuttisesti käyttökelpoisen farmaseuttisen aerosolikoostumuksen valmistamiseksi
ES2076279T3 (es) Medicamentos que, como principio activo, contienen acidos carboxilicos con contenido en azufre, asi como su empleo para combatir retrovirus.
Ginsburg et al. The effect of ferriprotoporphyrin IX and chloroquine on phospholipid monolayers and the possible implications to antimalarial activity
DK1768650T3 (da) Flydende depotformuleringer
PT1389089E (pt) Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água
PT93638A (pt) Processo para a preparacao de uma composicao para a aplicacao topica do acido da vitamina a
ES2186802T3 (es) Microemulsiones destinadas a usarse como vehiculos para la alimentacion de compuestos activos.
AR024013A1 (es) Preparado farmaceutico con diamorfina como sustancia activa, y su utilizacion en un procedimiento para el tratamiento de la adiccion a los opiaceos
JPH04226922A (ja) コントロール可能な皮膚浸透用局所組成物
BR0317340A (pt) Formulações de hfc em solução contendo tiotrópio
JPH08134026A (ja) アミノアルコール類の塩およびこれを含有する医薬処方物
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
Jones et al. Mechanism of toxicity of injected CS gas
EP0493496A1 (en) Ibuprofen triturates and topical compositions containing same
US2430450A (en) Antiseptic urea peroxide-glycerol solution
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
BR0312111A (pt) Formulação estável, lìquida, parenteral de parecoxib
KR950031084A (ko) 국소용 진양(鎭洋) 조성물
CO5021217A1 (es) Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas
US3070497A (en) Method of alleviating topical fungal infections
Proverbio et al. Ouabain-insensitive Na+-stimulated ATPase activity of basolateral plasma membranes from guinea-pig kidney cortex cells: II. Effect of Ca2+
WO1988003799A1 (en) Pharmaceutical vehicles for reducing transdermal flux
Takeuchi et al. Prostaglandins stimulate and inhibit acid secretion in amphibian fundic mucosa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed